Malmö Breast Tomosynthesis Screening Trial
This trial is active, not recruiting.
|Treatment||dbt and ffdm|
|Collaborator||Unilabs AB Sweden|
|Start date||March 2010|
|End date||December 2017|
|Trial size||15000 participants|
|Trial identifier||NCT01091545, Dnr 2009/770|
To compare digital breast tomosynthesis (DBT) with full field digital mammography (FFDM) regarding effectiveness as screening modalities.
|Intervention model||single group assignment|
Number of breast cancers detected by DBT
time frame: 24 months
Female participants from 40 years up to 74 years old.
Inclusion Criteria: - women 40-74 years old - in the regular population based mammographic screening program in Malmö, Sweden. Exclusion Criteria: pregnancy -
|Official title||Malmö Breast Tomosynthesis Screening Trial|
|Principal investigator||Sophia Zackrisson, MD PhD|
|Description||Mammography is the only approved method for breast cancer screening, but not all tumors can be detected with mammography. The main reason is overlapping structures that can either mimic or hide a tumor on a 2-dimensional image like mammography. Digital breast tomosynthesis, (DBT) is a 3-dimensional x-ray technique that has been developed during the last years. A tomographic technique like DBT, which reduces or eliminates the detrimental effect of over- and underlying tissue, can probably help to find more tumors. This study aims to investigate whether more breast cancers can be detected with DBT compared to full field digital mammography (FFDM) in population invited to screening. An interim analysis will be performed during 2013 including the first 7,500 women of the study cohort.|
Call for more information